NCT06073496

Brief Summary

Gynecological cancer is cancer that starts in the female reproductive organs. Pain in gynecological cancer can be caused by an underlying malignancy or surgical procedure as well as chronic pain associated with malignancy and sequelae of the therapy given. Gynecological cancer patients often experience moderate to severe pain and use higher levels of opioids than patients diagnosed with other cancers. More than two thirds of patients with advanced cancer experience severe pain and up to half of these patients report that their pain is not well controlled. This study aims to analyze the effectiveness of electroacupuncture plus standard therapy on pain intensity (VAS score), changes in analgesic dose, and quality of life (QLQ C-30 EORTC score) in patients with gynecological cancer pain compared to standard therapy alone.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
58

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Aug 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 30, 2023

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

October 4, 2023

Completed
6 days until next milestone

First Posted

Study publicly available on registry

October 10, 2023

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 19, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 19, 2023

Completed
Last Updated

January 29, 2024

Status Verified

January 1, 2024

Enrollment Period

4 months

First QC Date

October 4, 2023

Last Update Submit

January 25, 2024

Conditions

Keywords

ElectroacupunctureCancer painGynecological cancer painAcupunctureVASEORTC QLQ C 30Quality of LifeAnalgetic Dose

Outcome Measures

Primary Outcomes (1)

  • Pain severity with Visual Analog Scale

    Rating scale for measuring pain, where the minimum value is 0 = no pain, and the maximum value is 100 = severe pain. A higher scale means worse outcomes.

    Before treatment, After treatment in day 1, day 2, day 3, day 5 and day 7

Secondary Outcomes (2)

  • European Organisation for Research and Treatment of Cancer Quality of Life C30

    before treatment and 7 day after treatment

  • Analgetic Usage in dosage and frequency

    Before treatment, After treatment in day 1, day 2, day 3, day 5 and day 7

Study Arms (2)

Control

NO INTERVENTION

The Patient are cancer patient that experience cancer pain that only receive analgetic drug treatment according to WHO Stepledder of Pain

Electroacupuncture and standard Therapy

EXPERIMENTAL

The Patient are cancer patient that experience cancer paint that receive analgetic drug treatement according WHO stepledder of pain and receive electroacupuncture

Other: Electroacupuncture

Interventions

Patient receive analgetic medicine will get experimental procedure with needle insertion that attach to eletrostimulator

Electroacupuncture and standard Therapy

Eligibility Criteria

Age18 Years - 65 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsFemale with gynecology cancer
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Female 18 to 65 years old
  • Gynecocal cancer with pain ≥ 4 acording Visual Analog scale and receive analgetic medicine
  • The pain cause by
  • direct from cancer
  • Treatment proces surgery, radiotherapy, chemotherapy, paliatif treatment, supportive treatment
  • Adverse reaction form treatment and intoxication

You may not qualify if:

  • Emergency case patient with hemodynamic instable
  • Patient with uncooperative behavior because ith serious psychological disorders, no currently undergoing psychiatric treatment, aggressive behavior, that not allowed for acupuncture.
  • Patients with blood clotting disorders, with platelets \<50.000 and in neutropenic condition with \<1000 neutrophils.
  • The patient has an allergy to stainless steel acupuncture needles. Wounds at the acupuncture point puncture sites, skin infections in the ears. On patients with eczema on the ears, external otitis or psoriasis.
  • There is a tumor in the area that will be stabbed and stimulated in the stomach pregnant women, close to the heart, or in the area of the carotid sinus lymphedema, insertion into the prosthesis.
  • Patients with heart rhythm disorders. The patient uses a pace maker.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Fatmawati Hospital

Jakarta, DKI Jakarta, 12430, Indonesia

Location

Persahabatan Hospital

Jakarta, DKI Jakarta, 13230, Indonesia

Location

Cipto Mangunkusumo Hospital

Jakarta Pusat, DKI Jakarta, 10430, Indonesia

Location

MeSH Terms

Conditions

Cancer Pain

Interventions

Electroacupuncture

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Combined Modality TherapyTherapeuticsAcupuncture TherapyComplementary TherapiesElectric Stimulation TherapyPhysical Therapy ModalitiesRehabilitationTranscutaneous Electric Nerve StimulationAnalgesiaAnesthesia and AnalgesiaAnesthesia

Study Officials

  • KEPK FKUI-RSCM

    The Ethics Committee of the Faculty of Medicine, University of Indonesia

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
asessor
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Medical Doctor

Study Record Dates

First Submitted

October 4, 2023

First Posted

October 10, 2023

Study Start

August 30, 2023

Primary Completion

December 19, 2023

Study Completion

December 19, 2023

Last Updated

January 29, 2024

Record last verified: 2024-01

Data Sharing

IPD Sharing
Will not share

Locations